News

Oncternal Therapeutics will be the name of the combined company, which will engage in the development of potential first-in-class therapeutic candidates for cancers. As per terms of the

These two studies met their primary endpoints, showing that the combination of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine, injected every four weeks, was non-inferior in maintaining viral suppression

The committee concluded that Blincyto holds capacity to offer significant clinical benefits, while addition data on cost-effectiveness is required to evaluate its credibility for NHS funding. NICE has

Proceeds from the financing will be used to advance the company’s development of next-generation CRISPR technologies, expand its pipeline of base editing programs, and further extend its scientific

The case report, published in Nature and carried out with partners at the University of Cambridge and the University of Oxford, comes ten years after the first such

The 30-week long trial, dubbed Sustain 9, assessed the efficacy and safety of Ozempic injection 1.0 mg in combination with the SGLT-2 inhibitors against placebo. The drug was

Promacta (eltrombopag) is known as Revolade outside the US and is marketed worldwide by Novartis. This transaction is expected to close on Wednesday, March 6, 2019. “After extensive

The approval has been granted for Spravato for use in conjunction with an oral antidepressant in adults with TRD, who have cycled through multiple treatments without relief. Janssen

Fedratinib is a highly selective JAK2 inhibitor intended for the treatment of patients with myelofibrosis, a serious bone marrow disorder that disrupts the body’s normal production of blood